View Post

New insight into why malaria drugs work against some cancers could boost drug development

In Clinical Trials by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com There are currently about 20 clinical trials underway evaluating a class of malaria drugs known as chloroquines in several tumor types, including breast cancer, lung cancer and multiple solid tumors, according to ClinicalTrials.gov. Anti-malarial drugs, in fact, have long been of interest in the oncology community because of their ability to shrink some cancers. But …

View Post

First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02

In Clinical Trials by Barbara Jacoby

SOURCE: Translational Drug Development From: apnews.com Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited (Genzada), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 human clinical trial of the company’s flagship molecule GZ17-6.02 (6.02) for patients with advanced solid organ tumors or lymphoma. “We …

View Post

Experimental Immunotherapy Drug Shows Promise for Non-Hodgkin Lymphoma

In Clinical Trials by Barbara Jacoby

From: everydayhealth.com What’s New A small, early-phase clinical trial testing a new drug combination produced impressive outcomes for patients with relapsed or refractory non-Hodgkin lymphoma, according to a report published November 1, 2018, in the New England Journal of Medicine. Researchers at multiple institutions tested an experimental drug known as 5F9 with the standard cancer drug Rituxan (rituximab) in 22 people. Eleven of the …

View Post

Norwalk Hospital reports positive results with breast cancer clinical trials

In Clinical Trials by Barbara Jacoby

By: Kevin Zimmerman From: westfaironline.com Four cutting-edge breast cancer clinical trials recently launched at Norwalk Hospital’s C. Anthony and Jean Whittingham Cancer Center are giving hope to patients diagnosed with triple negative breast cancer, an aggressive form of the disease that cannot be treated with hormone therapies or other cancer-fighting drugs. “We started about six months ago,” said Dr. Linda …

View Post

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

In Clinical Trials by Barbara Jacoby

Source: upmc.com From: news-medical.net Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the …

View Post

Immunotherapy trial offers new hope for people with aggressive breast cancer

In Clinical Trials by Barbara Jacoby

Source: qmul.ac.uk From: news-medical.net There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer. New research led by Queen Mary University of London and St Bartholomew’s Hospital has shown that by using a combination of immunotherapy and …

View Post

FREE Immunotherapy Patient Summit – Houston, Sat, December 8, 2018

In Clinical Trials by Barbara Jacoby

From: CANCER RESEARCH INSTITUTE Date and Time:  Sat, December 8, 2018 – 10:00 AM – 3:30 PM PDT Hosted at MD Anderson Cancer Center Dan L. Duncan Cancer Prevention Building, (CPB) – 8th Floor Conference Center 1155 Pressler Street Houston, TX 77030 Learn about the basics of cancer immunotherapy, a highly promising new approach to cancer treatment. Medical experts along with …

View Post

9 things to know about CAR T-cell therapy

In Clinical Trials by Barbara Jacoby

By: Cynthia DeMarco From: mdanderson.org CAR T-cell therapy is a new type of cancer treatment offered at MD Anderson through clinical trials and FDA-approved standard of care cell therapy products. But what exactly is CAR T-cell therapy? And who should consider it? We spoke with Sattva Neelapu, M.D., to learn more. Here’s what he had to say. Let’s start with the …

View Post

Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors

In Clinical Trials by Barbara Jacoby

Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the company’s lead compound ONC201. The article identifies several opportunities to use …